Partners Capital Investment Group Holdings LLC Takes Position in Mylan N.V. (MYL)

Partners Capital Investment Group Holdings LLC purchased a new stake in shares of Mylan N.V. (NASDAQ:MYL) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 20,475 shares of the company’s stock, valued at approximately $642,000.

Several other hedge funds have also recently made changes to their positions in MYL. Meeder Asset Management Inc. boosted its stake in shares of Mylan by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after purchasing an additional 1,475 shares in the last quarter. BT Investment Management Ltd acquired a new stake in shares of Mylan during the third quarter valued at about $142,000. Global X Management Co. LLC raised its position in shares of Mylan by 59.2% during the second quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock worth $186,000 after acquiring an additional 1,786 shares during the last quarter. Doliver Capital Advisors LP bought a new position in shares of Mylan during the second quarter worth about $201,000. Finally, Eagle Global Advisors LLC bought a new position in shares of Mylan during the second quarter worth about $205,000. 73.86% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently issued reports on the company. UBS set a $46.00 price objective on Mylan and gave the stock a “buy” rating in a research report on Monday. ValuEngine upgraded Mylan from a “hold” rating to a “buy” rating in a research report on Friday. Cantor Fitzgerald set a $34.00 price objective on Mylan and gave the stock a “hold” rating in a research report on Thursday, November 30th. Zacks Investment Research downgraded Mylan from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Finally, Royal Bank Of Canada raised their price objective on Mylan from $32.00 to $37.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $41.49.

Shares of Mylan N.V. (MYL) opened at $37.44 on Tuesday. The firm has a market capitalization of $20,448.95, a P/E ratio of 8.11, a price-to-earnings-growth ratio of 2.09 and a beta of 1.38. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. Mylan N.V. has a 1-year low of $29.39 and a 1-year high of $45.87.

Mylan (NASDAQ:MYL) last issued its earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). The business had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.38 earnings per share. equities analysts anticipate that Mylan N.V. will post 4.56 EPS for the current year.

WARNING: This piece of content was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/05/partners-capital-investment-group-holdings-llc-takes-position-in-mylan-n-v-myl.html.

Mylan Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit